NORML

JULY 18, 2024

The post American Nurses Association Provides Public Comments to DEA in Support of Reclassifying Cannabis appeared first on NORML. ANA strongly supports the currently accepted medical use of cannabis to alleviate disease-related symptoms and side effects."

DEA 318

DEA Cannabis Access 318

NORML

NOVEMBER 1, 2024

NORML's Deputy Director Paul Armentano said that he was disappointed but hardly surprised by the DEA's decision to disproportionately include groups opposed to marijuana policy reform as designated participants. The post DEA Judge Pushes Back Timeline for In-Person Testimony in Marijuana Rescheduling Hearing appeared first on NORML.

DEA 233

DEA Marijuana Policy Law 233

NORML

MAY 24, 2021

The DEA’s website did not provide a timeline as to when it anticipates finalizing the applicants’ grow authorizations or when it plans to take actions on the dozens of remaining applications that are still pending before the agency. The post DEA Announces Intent to License Marijuana Growing Applicants appeared first on NORML.

DEA 246

DEA Marijuana 246

NORML

JUNE 3, 2020

According to a DEA memorandum , the agency requested to expand its policing powers beyond the enforcement of federal drug laws to include the enforcement of “any federal crime committed as a result of protests over the death of George Floyd.” The DEA possesses the power to strictly enforce these violations of law.

DEA 278

DEA Law Marijuana Events 278

Americans for Safe Access

AUGUST 27, 2024

In light of the Drug Enforcement Administration’s (DEA) announcement to schedule a hearing on the rescheduling of cannabis, Americans for Safe Access (ASA) emphasizes the urgent need for compassionate leadership in Congress to advocate for the rights of medical cannabis patients. For Immediate Release: August 28, 2024 Washington, D.C. —

DEA 262

DEA Access Patients Cannabis 262

NORML

MARCH 3, 2021

The post DEA Report: Marijuana Seizures at Southern Border Have Fallen Significantly Following Passage of Statewide Legalization Laws appeared first on NORML. “In US markets, Mexican marijuana has largely been supplanted by domestic-produced marijuana. CBP marijuana seizures along the SWB have decreased more than 81 percent since 2013,".

DEA 246

DEA Law Legalization Marijuana 246

NORML

AUGUST 2, 2019

” To date, however, the agency has neither affirmed or denied any of the 26 applicants that have sought the DEA’s permission for a federal cultivation license. Read NORML’s new op-ed, “Three years ago the DEA said they would remove roadblocks to cannabis research — they still haven’t, here.).

DEA 216

DEA Cultivation Marijuana Policy 216

NORML

AUGUST 26, 2019

The US Drug Enforcement Administration (DEA) has once again pledged to take action to better facilitate clinical cannabis research. In 2016, the DEA similarly announced the adoption of new rules to expand to supply of research-grade cannabis, but failed to take any further action.

DEA 193

DEA Cultivation Compliance Compliance 193

NORML

JUNE 16, 2022

The post DEA Reports Significant Uptick in Marijuana-Related Seizures, Arrests appeared first on NORML. The totals are the highest reported by the agency since 2011, when it reported making an estimated 8,500 marijuana-related arrests and seized some 6.7 million plants via its domestic eradication program.

DEA 190

DEA Marijuana Programs Law 190

NORML

MAY 23, 2023

The post DEA Reports More Marijuana Seizures, Fewer Arrests in 2022 appeared first on NORML. Federal law enforcement agents and their partners seized nearly 5.7 million cultivated marijuana plants in 2022. This is the highest annual seizure total reported by the agency since 2011.

DEA 187

DEA Marijuana Cultivation Law 187

NORML

APRIL 8, 2020

As a result, the DEA has been encouraged for over a decade to expand the pool of federally licensed cannabis producers — a move that the agency has largely resisted. To date, however, the DEA has failed to either affirm or reject any of the more than 30 applications it has received.

Cultivation 340

Cultivation DEA Clinical Trials Marijuana 340

Project CBD

NOVEMBER 8, 2021

Psilocybin, the psychedelic mushroom extract, has been fast-tracked by the FDA to treat depression, but doctors still can’t use it in their practice.

DEA 348

DEA Patients Extraction 348

NORML

JULY 16, 2019

According to figures published in the DEA’s Domestic Cannabis Eradication/Suppression Statistical Report, the agency and its law enforcement partners confiscated an estimated 2.82 million marijuana plants nationwide in 2018. million in 2017 to 1.4 million in 2018. Adult-use retail sales of cannabis began in California in 2018.

DEA 178

DEA Marijuana Data Retail 178

NORML

OCTOBER 1, 2024

The post NORML Files Notice of Intent to Participate in DEA’s Marijuana Rescheduling Hearing appeared first on NORML. "We believe NORML has well earned a seat at the table, and that it is in the public interest for it to be heard."

DEA 315

DEA Marijuana Advocacy 315

Leafly

JUNE 8, 2020

The DEA's five-part test to determine 'currently accepted medical use' is flawed, say the plaintiffs. The post New lawsuit aims to force DEA to reschedule marijuana appeared first on Leafly.

DEA 145

DEA Marijuana Cannabis 145

Americans for Safe Access

NOVEMBER 3, 2024

TAKE A BREATH The Administrative Law Judge recently postponed the DEA’s highly anticipated rescheduling hearing and released the DEA’s witness list, prompting speculation, conspiracies, and anxiety about the delay and the agency’s next moves. Before you pull your hair out, read these five essential points to put your mind at ease.

DEA 293

DEA Law 293

NORML

APRIL 13, 2021

The post NORML Comments on Biden’s Pick for DEA Administrator appeared first on NORML. Former NJ Attorney General to be Nominated to Lead Agency.

DEA 151

DEA Law 151

Medical Marijuana Pages

OCTOBER 9, 2024

DEA Potential Reclassification of Marijuana Policy. In recent discussions surrounding drug policy reform, the reclassification of marijuana by the Drug Enforcement Administration (DEA) has emerged as a pivotal issue. Read More

DEA 122

DEA Policy Marijuana Cannabis 122

Leafly

MAY 18, 2021

The post DEA finally ends fed monopoly on schwaggy research-grade cannabis appeared first on Leafly. Goodbye, Mississippi ditch weed. Hello, real-world high-quality cannabis.

DEA 145

DEA Cannabis 145

Leafly

OCTOBER 17, 2022

The post DEA wants to boost production of cannabis and psychedelics research in 2023? The Drug Enforcement Administration wants to increase the amount of cannabis and psychedelics it researches in 2023. appeared first on Leafly.

DEA 140

DEA Cannabis 140

Americans for Safe Access

JANUARY 15, 2025

DEA Postponed Rescheduling Hearing, What Just Happened? Join ASA staff as we dive into the new ruling to postpone the DEA hearings, what it means for the current rescheduling process, and where we go from here. SafeAccessNow.org

DEA 254

DEA 254

Canna Care Docs

OCTOBER 10, 2024

Drug Enforcement Administration (DEA) will move to reclassify cannabis — a historic shift that could have wide ripple effects across the country. Understanding current drug scheduling for cannabis The DEA classifies drugs, substances, and certain chemicals used to make drugs into five distinct categories or “schedules.”

Patients 111

Patients DEA Research and Development Recreational 111

Leafly

APRIL 6, 2020

The post DEA loosens rules on prescription CBD drug Epidiolex appeared first on Leafly. Prescription CBD tincture Epidiolex is coming to more patients. Cost: $32,500 per year.

DEA 131

DEA CBD Tincture Patients 131

Americans for Safe Access

MARCH 12, 2025

While Schedule III may seem like a large deviation from the recommendations provided by HHS and DEA in 2016, outright dismissing the finding of HHS and DOJ, currently accepted medical use does not take into account the enormity of the scientific and medical discoveries that have happened in the time since they were issued as well as the vast societal (..)

DEA 130

DEA Policy Cannabis 130

NORML

MARCH 26, 2020

The DEA now estimates that, under the new rules, it may approve between three and 15 total applicants. ” He added, “Further, the DEA has an incredibly poor track record in this arena – having for years now promised to expedite and streamline this process, but failing to deliver.

Cultivation 242

Cultivation DEA Extraction THC 242

Americans for Safe Access

NOVEMBER 6, 2024

We will discuss the impacts of the election, a potentially jam-packed lame-duck session, National Days of Action, the DEA rescheduling hearings, and preparing for the 47th president & 119th Congress. Join ASA Staff, Advisors, Chapters, Members, & Affiliates for this post-election webinar. Add to Google Calendar Zoom Link: [link]

DEA 281

DEA 281

Americans for Safe Access

JUNE 2, 2020

On March 23, DEA published a proposed rulemaking —“Controls to Enhance the Cultivation of Marihuana for Research in the United States”—in the Federal Register (85 FR 16292), involving who can grow cannabis in bulk for research purposes.

Clinical Trials 264

Clinical Trials DEA History Programs 264

Americans for Safe Access

APRIL 19, 2022

When we started Americans for Access, we were facing paramilitary style raids from the DEA, only 8 states had passed laws creating criminal exemptions for medical cannabis patients, the DEA was still saying that cannabis was a gateway drug and there was no legal access anywhere! And look at the world that you have helped create!

DEA 264

DEA Access Patients Law 264

Americans for Safe Access

JULY 24, 2024

Now that public comment has closed the rescheduling process shifts to the Drug Enforcement Administration (DEA).

DEA 281

DEA Access Cannabis 281

Leafly

AUGUST 26, 2019

Two days before a federal court deadline, the DEA says it will do what it said it would do three years ago. The post DEA Says It Will Finally Let Others Grow Research-Grade Cannabis appeared first on Leafly.

DEA 111

DEA Cannabis 111

WeedAdvisor

JULY 4, 2019

Despite mounting evidence into cannabis’ therapeutic benefits, the DEA continues to close its eyes and plug its ears, constantly claiming that there is not enough research to support its medicinal value, according to Marijuana Moment. It could be argued that the DEA is hesitant for the sake of public safety.

DEA 111

DEA Research and Development Clinical Trials Cultivation 111

Cannabis Law Report

AUGUST 27, 2021

The language is general but it looks like the DEA will be trying to nip supply in the bud at source. WASHINGTON – The Drug Enforcement Administration today announced a comprehensive review of DEA’s international operations and foreign footprint, including administrative and financial support for those operations from DEA headquarters.

DEA 105

DEA Safety Programs Law 105

Veriheal

APRIL 25, 2024

One Arizona church, known as the Church of the Eagle and the Condor (CEC), recently settled a lawsuit with the Drug Enforcement Agency (DEA), the Department of Homeland Security (DHS), and other federal agencies. The DEA will also take samples of shipments to ensure that the only substance entering the country is ayahuasca.

DEA 111

DEA History Access Medicine 111

Leafly

MARCH 22, 2019

The post CVS Ignores DEA, Says It’s Already Selling CBD Products appeared first on Leafly. The nation's largest drugstore chain is selling CBD products in 8 states. Meanwhile, independent CBD stores are being raided by police in Texas.

DEA 112

DEA CBD 112

Cannabis Law Report

OCTOBER 27, 2020

A vague memory tells us that the DEA were looking for a contractor early 2019 ? The post DEA - We're Still Burnin' Weed first appeared on Cannabis Law Report. What happened to the last contractor. Marijuana Moment has … Read More.

DEA 98

DEA Law Marijuana Cannabis 98

Cannabis Law Report

DECEMBER 3, 2020

The post DEA Asks Court To Overturn Cannabis Rescheduling Appeal first appeared on Cannabis Law Report. Drug Enforcement Administration reiterated that a lawsuit challenging marijuana’s classification as a Schedule 1 drug under the federal Controlled Substances Act should be … Read More.

DEA 114

DEA Cannabis Law 114

MJ Business Attorneys

JUNE 29, 2018

Moreover, the ball is in the Drug Enforcement Agency’s (DEA) court. The FDA can make recommendations to the DEA about substances subjected to scheduling under the CSA, but the DEA is the entity with the power to reschedule CBD. In the recent case Hemp Industries Associations v.

DEA 113

DEA CBD Pharmaceutical Research and Development 113